Enterprise League logo

Biotechnology Companies in Europe

Biotechnology companies develop, manufacture, and distribute medical devices, diagnostics, or pharmaceutical products for use in clinical, hospital, and research settings. This page lists companies operating in the Biotechnology sector based on self-reported profile data. The directory currently holds 480 companies in this sector. The largest share of listings is based in London. Related sectors on Enterprise League include Medical Equipment and Services, Life Science, Genetics, Pharmaceutical, Biopharma, Clinical Trials, Nanotechnology.
480 companies
London top city

Europe
Biotechnology
List of Biotechnology companies in Europe

480 companies

Sort by

We bring automated cell-monitoring solutions for cell & gene therapy, vaccine industry and life sciences applications. Our microscopes are easy-to-use, label-free and non-invasive tools for the three-dimensional, real-time imaging of living cells. Based on patented differential digital holography technology, our advanced systems generate reliable, high-quality holographic images providing highly-reproducible tracking of: - cell density - morphology - cell viability - viral infection kinetics - cell activation status Direct Benefits Our technology can benefit a range of applications, from R&D to manufacturing processes, and enable significant cost reduction and quality improvement. Our microscopes are particularly convenient and robust for automated cell culture monitoring, analysis and quality control.
Medical Equipment and Services
Health and Medical Products
Software
3D Technology
Biotechnology
Life Science

2010

At Sano, our mission is to accelerate the future of personalised medicine. Our patient finding and engagement services enable researchers to deliver precision medicine clinical trials at increased speed and lower cost. Sano's end-to-end Platform integrates with your existing providers and partners, including sites, medical record retrieval services, sample collection and data analysis partners, and we apply our expert knowledge to identify new and highly efficient channels for finding and engaging the patients you need to support your project.
Biotechnology

2016

Saphetor SA, is a global precision-medicine company dedicated to large-scale identification and interpretation of human genetic variants by leveraging proprietary algorithms and expert domain knowledge. Saphetor is the creator of VarSome, a suite of intuitive and data-driven bioinformatics solutions for clinicians and researchers. VarSome is powered by a Molecular DB with over 130 integrated and harmonized genomic data sources, linked by AI to over 32 million publications. Thanks to VarSome’s global community of over 450 000, the database is further enriched by additional unique user-generated annotation. Saphetor has developed proprietary algorithms to automate variant classification based on industry-standard ACMG and AMP guidelines for interpretation of germline and somatic variants, as well as CNVs. The VarSome suite offers solutions for individuals needing a powerful Search tool to support research, professional labs requiring a CE-IVD and HIPPA-compliant platform to Analyze NGS samples, and bioinformaticians wanting to use our simple API to access our database and classifiers and integrate into existing Code.
Biotechnology

2014

Scenic Biotech is applying a novel approach to target discovery by harnessing genetic suppressors. Powered by our proprietary technology, Scenic scientists are obtaining a unique and more comprehensive understanding of disease biology. These insights enable us to rapidly identify and validate novel drug targets and then focus on the development of medicines with the greatest potential to impact the lives of patients.
Biotechnology

2017

Science Creates is a deep tech ecosystem, supported and backed by successful entrepreneurs, that enables scientists and engineers to accelerate their ideas and build disruptive businesses. Our growing network of scientific startups are solving global problems with groundbreaking advancements in healthcare, the environment and quality of life. We have two research facilities in Bristol, a venture capital arm that offers investment into early-stage and scale-up deep tech companies, and an educational outreach charity. Our mission is to solve the world’s biggest challenges through deep tech.
Biotechnology

2020

SELFDIAGNOSTICS next-generation molecular diagnostics Multitest platform is an innovative tool for launching a family of rapid molecular tests. > MULTITEST COVID-19 https://selfdiagnostics.eu/rapid-pcr-covid-multitest Selfdiagnostics Multitest COVID-19 – the rapid molecular NAAT test combines the ease of use of rapid tests and the diagnostic accuracy of laboratory PCR. ☉ PCR-LEVEL TESTING WITHOUT INVESTMENT. Very straightforward single-use test requires no investment in instruments or infrastructure. No maintenance contracts. No calibration. ☉ UNLIMITED THROUGHPUT. Each test runs independently – there is no need to wait for an instrument to finish the previous test. ☉ EASY AND PORTABLE. Just swab and test – does not require any training. The single-use test is just slightly larger than a credit card. Room temperature stable. A good fit for the following settings: ☉ HOSPITALS to increase rapid PCR testing in emergency departments and on wards immediately without investment in additional instruments. ☉ SMALL CLINICS to have modern PCR testing results without the need to set up a big lab or outsource a PCR testing service. ☉ TESTING SERVICE PROVIDERS to offer rapid PCR results for certificates or immediate diagnostics decisions. ☉ COMPANIES to keep production facilities open by discovering infected individuals reliably and rapidly. MULTITEST LONG-TERM ADVANTAGES: ☉ MASS-PRODUCIBLE. Intentionally simple and minimal component design for cost efficient mass production. Modular production line enables fast production scale-up. ☉ MULTIPLEXED. Able to differentiate up to four different organism’s RNA or DNA from one sample in a single run. Duplex panel test – Selfdiagnostics STD Multitest CT/NG is ready to be launched next after validation. ☉ EXPANDABLE. Has proven multi-sample capability. Tests from swab and urine samples are ready. Expandable to detect from blood, soil and water. IN THE PIPELINE: > MULTITEST STD https://selfdiagnostics.eu/std-multitest
Biotechnology

2008

Providing genomic analysis to everybody. SeqOne is a company focused on developing state-of-the-art genomic analysis tools for clinical applications in the fields of cancer and rare disease. The company's vision is to develop a genomic analysis system that dramatically reduces the cost and resources needed to provide accurate genomic analysis. Our aim is to make genetic testing easier and more accessible in order to accelerate the adoption of personalized medicine. SeqOne’s platform makes it possible to efficiently analyze "high resolution" next generation sequencing (NGS) data, providing a complete list of all genetic variants and prioritizing them in order of relevance. The platform uses a proprietary machine learning-based variant prioritization engine designed to identify variants that are medically relevant to each specific patient. SeqOne bioinformatics (genomic analysis algorithms) are organized by applications, which provide accurate answers to medical questions that influence patient treatment, in both constitutional and somatic pathologies. SeqOne offers applications to analyze a single-patient or an entire family to diagnose hereditary family disorders, detecting complex events such as large structural modifications or transposable elements. In the field of somatic cancer, applications can analyze tumor-only, compare healthy versus tumoral samples, or hematological cancers identifying relevant variants, such as somatic CNV, TMB, MSI, or fusion genes, as well as suggest therapeutic options. The SeqOne platform addresses the operational challenges of performing NGS analysis at scale, including secure data storage, management of process quality, and traceability needed for certification. We adopt a unique approach to process quality control that addresses ongoing process monitoring as well as changes to upstream lab procedures.
Biotechnology

2017

Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing an internal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
Biotechnology

2017

-Long history in research and biotech- Uniq Bioresearch Ltd. is a Finnish privately held company. It was established in 1996 and since the company has invested in developing ACTIWHEY®, activated whey protein based products and solutions including microencapsulation, coatings and films for businesses and whey protein products for consumers. -Several patents- We have developed a gentle method to activate whey protein. Our whey based solutions have already 3 patents, that are valid in more than 10 countries. -Wellbeing and sustainability are key priorities- Our products are designed to improve people’s and animals’ wellbeing. Sustainability is a top priority in our operations. -Only the best quality will do- All our products are made in Finland and we accept only the best quality for our raw materials.
Biotechnology

1996

We are experts in developing novel sub-unit vaccines Our initial focus is on animal health. We aim to capitalize on the first approval of a CrisBio® - based vaccine dossier (expected in 2020) to expand into human health and thereby fully exploit the platform’s potential. CrisBio® also has applications in the Diagnostics sector, where it is already being exploited by a commercial partner. Our current portfolio comprises 6 vaccines across livestock species. Proof of concepts have been generated in > 20 additional vaccine antigens Value through collaborations Our go to market strategy is inherently linked to collaborations. We offer: • Development of tailor-made baculovirus vectors optimized for industrial production. • Proof-of-concept studies to validate the production of recombinant proteins in CrisBio®. • Supply of recombinant proteins produced in CrisBio® through license agreements. • Development of proprietary portfolios. Algenex is led by an internationally experienced management team, that is supported by a well-balanced Strategic Advisory Board that combines industry and investment experience.
Manufacturing
Pharmaceutical
Biotechnology

2005

biomodal is an omics based life-sciences technology and analytics company delivering products that bring the dynamism of our ever-changing biology into focus. Our duet multiomics solution enables more epigenetic information from a single, low input DNA library without complex, resource intensive bioinformatics or harsh chemical treatment. Our single-base-resolution, phased sequencing approach unlocks the combinatorial power of genetic and epigenetic information in one workflow, elucidating greater biological insight within the fields of cancer, neurodegenerative disease, and ageing.
Biotechnology

2012

Maintaining musculoskeletal health is the keystone of overall health as we get older. As we age our physical condition gradually deteriorates, leading to loss of strength, fitness and mobility. In most cases, this isn’t due to a simple decision to stop exercising. It is due to the breakdown of musculoskeletal function caused by disease. Musculoskeletal diseases such as osteoarthritis, tendinopathy and lower back pain are the primary causes of disability and early retirement in people over the age of 65. Currently, there are no approved disease-modifying drugs for these diseases, meaning that physical decline in old age is inevitable. At Causeway, we believe that physical decline in old age is not inevitable and in indeed may be reversible. To address this, we are developing a range of therapies that treat common MSK diseases that will allow us to remain fit and active into our nineties and beyond. Staying active as we get older also reduces the risk of developing osteoporosis, dementia, diabetes, obesity, cancer and cardiovascular disease. Finding a way to remain fit and active as we age isn’t just a personal imperative but also a global one. By 2050, one in four of us will be over 65 years old, the number of people age over 80 is projected to triple and retirement age to rise to 75-80 years old. As individuals and as a society, we need to find solutions to the problems of ageing. Our goal is to develop therapies that treat the most common MSK diseases, such as osteoarthritis, tendinopathy and lower back pain, re-defining what old age looks and feels like.
Pharmaceutical
Biopharma
Healthcare
Biotechnology
Therapeutics

2017

Founded in 2014, Edinburgh Molecular Imaging (EM Imaging) is a clinical phase biotechnology company focused on enabling image guided therapy. The company’s molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue. The focus of EM Imaging is the discovery and development of small molecules and peptides that, when conjugated with fluorescent dyes, target and specifically cancerous cells and other diseased tissue. This illumination will provide the clinician with a clearer view and decision-making tool to benefit the patient.
Biotechnology

2014

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx’s first experimental medicine, efgartigimod, is being evaluated in multiple autoimmune diseases, including myasthenia gravis (MG), pemphigus vulgaris (PV), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). argenx is located in Ghent, Belgium, Boston, Massachusetts and Tokyo, Japan.
Clinical Trials
Biotechnology
Therapeutics

2008

Our company has the purpose of bridging the gap between insects & food companies so we can create the future of food Now! “We believe in a greener and healthier future, and we know is possible by changing the base of production without waiting for consumer behavior to change. There is an urgent need for better, safer and more sustainable sources of food ingredients and materials for the food industry. We can do this using biotechnology & data science to unlock the potential of insects as ingredients, biomaterials & many more to be discovered.” Alejandro Ortega, CEO & Founder Daniela Arias, COO & Founder Inspired by their culture Daniela and Alejandro named the company after the primary deity in the Talamancan mythology of Costa Rica, is the creator of Earth and humanity, god of wisdom and taught the values using natural resources in a responsible way and with harmony. We help insect ingredient manufacturers meeting the requirements of food companies & food brands, which requires improving the qualify and functionality of their current materials using new and innovative process optimization technologies we develop. Together with this we focus on accelerating the innovation & development using data science for targeted ingredient discovery, to create clean, efficient, and sustainable insect-based bio-active components including protein, fats and chitosan, as highly functional food ingredients for food manufacturers. And we can do it thanks to our unique green Isolation technology called Entowise®, which unlocks the potential of insect-bioactive components and improves the application of these materials as ingredients for food production. The Entowise® technology helps insect manufacturers to develop high value added and easy to use ingredients for food manufactures. Our technology and approach help food manufacturer reduce CO2 emissions up to 95% compared with current alternatives, while also improve the health of their end consumer
Dietary Supplements
Food Vendors
Advanced Materials
Biotechnology

2021

Limula provides an innovative solution for the production of the most personalised cancer treatments on demand and at scale. Our product is a unique proprietary platform can perform multiple steps of cell therapy manufacturing in a single device, using end-to-end automation and integrated process analytics.
Biotechnology

2020

Hertility is a women’s health company built by women, for women. We’re shaping the future of reproductive healthcare by pioneering unique diagnostic testing that provides data-driven and advanced insights into reproductive health, fertility decline and the onset of menopause. We provide expert advice, education and access to care - all from the comfort of your home. Our research trials are a step towards fixing the currently flawed system. 31% of women will suffer from a reproductive health issue at some point and through our research, we aim to reduce the time to diagnosis through advanced at-home testing and specialist gynaecological care. We tailor pathways to the individual's reproductive goals, whether it be to explore their ovarian health and fertility options or overall hormonal health, such as confirming a PCOS diagnosis. Currently, we can diagnose 9 of the most common gynae pathologies which may lead to reduced fertility and signpost gynae cancers. Ultimately, our aim is to change attitudes around reproductive health, both for individuals and in the workplace, and to encourage women to be proactive by tracking their reproductive health. We’re calling this the Reproductive Revolution!
Medical
Healthcare
Biotechnology

2019

UTILITY therapeutics Ltd., a biotechnology company focused on the U.S. development and commercialization of two European-approved antibiotics for the treatment of urinary tract infections (UTI, to address the significant threat faced by healthcare systems and patients from multi-drug resistant bacterial infections. The World Health Organisation has stated that antibiotic resistance is one of the biggest threats to global health, food security, and development today. Pivmecillinam is an oral prodrug of mecillinam that is being developed for uncomplicated UTI (uUTI), and it has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended-spectrum beta-lactamases. Mecillinam, an intravenous (IV) formulation, is being developed as a first-line therapy for complicated UTI (cUTI) in the hospital setting.
Biotechnology

2017

Valo Therapeutics (ValoTx) is a developer of novel immunotherapies in cancer and infectious disease. Our unique approach to immunotherapy, based on oncolytic viruses and viral vectors combined with disease-specific peptides, delivers highly adaptable and immunogenic therapeutic vaccination platforms. A spin-out company from the University of Helsinki, Finland, Valo Tx has assembled a talented team of immunotherapy experts, who together with the founding scientists have the necessary expertise to take its patented technology through clinical development and make it available to patients. The management team has a proven track record of developing successful companies from a laboratory idea to a full stock exchange listing.
Biotechnology

2016

THYTECH is a spin-off of the Gregorio Marañón Health Research Institute (IISGM) that was created with the aim of transferring to the patient our patented technology for the treatment of diseases related to immune disorders. The company arises from the work carried out by the researchers of the Immunoregulation Laboratory, and our main asset is a cellular therapy with thyTreg cells that is pioneering in the world that can establish a new paradigm in the prevention of transplant rejection and in the treatment of autoimmune diseases and clinical worsening of COVID patients.
Biotechnology

2022

TILT Biotherapeutics Ltd is a clinical stage company working in oncology towards enabling T-cell therapies and immune checkpoint inhibitors with oncolytic viruses. Embodiments of the technology will be used to enhance tumor infiltrating lymphocytes (TILs), chimeric antigen receptor T cells (CAR T) and immune checkpoint inhibiting antibody therapies. TILT was founded by Pr. Akseli Hemminki, who has published hundreds of papers in the field and treated almost 300 patients with 10 different oncolytic viruses. In 2013, Pr. Hemminki started his second company, TILT Biotherapeutics Ltd, with a technology based on his past findings in the lab, but more importantly in the clinic. The research conducted by TILT alone or in collaboration with some of world’s leading research groups with synergic technologies has generated very excellent results. The lead candidate is a clinical stage TNFα/IL2 armed oncolytic adenovirus (TILT-123 or Ad5/3-E2F-delta24-hTNFα-IRES-hIL2). Multiple Phase I clinical trials are ongoing. For contact: BD (at) tiltbio.com
Biotechnology

2013

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. The ongoing Phase 1a clinical study will assess safety, tolerability, and blood-brain barrier penetration of subcutaneously administered HER-096. Top-line data is expected by the end of 2023. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Biotechnology

2008

Libre Foods is the first biotech and climate-driven company to develop whole-cut meats such as "chicken" breast and steak from the power of fungi through biomass fermentation. 🍄 Libre Bacon, their first product to hit the market in 2022, is made from all-natural ingredients, and its core ingredient is mushrooms. Libre Bacon has been greatly received by Madrid, Barcelona, and Valencia restaurants and will soon be getting into people's homes. Libre Bacon is only the first step in Libre's journey to creating a more just, sustainable, and free future for all. A future where you can enjoy your Sunday breakfast, late-night burger, or midweek lunch while caring for yourself, others, the animals, and the planet. All at once. The Libre team believes in fungi to minimize the environmental impact of food production and the power of biomass fermentation to push food technology's boundaries—the mixture of these two variables has already shown significant progress in creating delicious and environmentally friendly meat alternatives. Reach out to find out how significant... 😎
Biotechnology

2021

Our mission is to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilars.
Pharmaceutical
Biotechnology
Life Science

2013

Bitbrain was founded in 2010 as a spin-off company of a research team from the University of Zaragoza, pioneer in approaching brain-computer interface applications outside laboratory investigation settings. Its DNA holds all knowledge in neurotechnology, biomedical engineering, artificial intelligence and data science accumulated at the university since 1998. Nowadays, the R+D+I bet is still strong, which has converted the company in a world reference for B2B neurotechnology solutions.
Market Research
Healthcare
Biotechnology
Neuroscience
Wearables

2010

Aquaporin is an innovative water technology company with operations in Denmark (HQ), Singapore, Turkey, the United States, and China. We are committed to rethinking water filtration with biotechnology to solve global water challenges. By combining three disciplines from the world of natural sciences: biology, chemistry, and physics, we have created the unique, nature-inspired Aquaporin Inside® technology which we embed into all our membranes and solutions. Our technology is based on Nobel Prize-winning research and is used to clean and reuse water in industries, in our homes, and even by NASA in space. We work with customers and partners around the globe to responsibly treat industrial wastewater, concentrate food and beverage products in a natural way, and enhance drinking water quality and accessibility.
Biotechnology

2005

We are a clinical stage biopharmaceutical company developing developing breakthrough immunomodulatory drugs for the treatment of cancer and inflammatory diseases. We have developed two highly promising pipelines of clinical and pre-clinical candidates with a focus on cancer and auto-immune diseases: - OncoMimics™: highly effective, off-the-shelf therapeutic vaccines against cancers (EO2401, EO2463). EO2401 is in Phase 1/2 clinical trials in patients with glioblastoma and adrenal tumors. EO2463 is in a Phase 1/2 clinical trial for indolent non-Hodgkin B-cell lymphomas. - EndoMimics™: a pipeline of next generation bioactives acting like human hormones or cytokines for the treatment of immune diseases. EB1010, the lead candidate, is a potent local inducer of IL-10 designed to provide improved therapeutic outcomes for patients with IBD. In addition, Enterome’s clinical candidate sibofimloc (also referred to as TAK-018) is advancing through a Phase 2 clinical trial in post-operative Crohn’s disease. Sibofimloc has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US.
Biotechnology

2011

Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases. Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.
Biotechnology

2014

Hidden within our planet's vast biodiversity are solutions to some of humanity's greatest challenges, with the potential to deliver sustainable food supplies, revolutionary manufacturing capabilities, and a new generation of medicines. At Basecamp Research, we are building BaseDiscovery, a platform technology that will use next-gen DNA analysis and environmental monitoring to connect the dots and improve our understanding of the natural world. Our team uses a unique and fully portable laboratory capable of rapidly analysing nature anywhere on Earth, discovering novel solutions to the world's most pressing challenges.
Biotechnology

2019

A proprietary light-driven, protein expression technology that uses chloroplasts to make extraordinarily high yields of proteins in plants. This game-changing manufacturing system is sustainable, free of animal pathogens and bacterial endotoxins, and highly scalable. Suitable for the recombinant protein contract manufacturing and development market. Bright Biotech is currently producing recombinant growth factors, which aid cell growth to promote regenerative medicine practices, and also industry processes such as clean meat production.
Biotechnology

2019

Canax is an italian company specialized in CO2 supercritical extraction and purification of compounds derived from Cannabis. Thanks to the use of the most modern technologies and a deep knowledge of the subject, Canax estracts 99,9x% isolated CBD for pharmaceutical, cosmetical, food and veterinary use.
Biotechnology

2019

We are a Danish biotech startup based in Søborg, with global ambition. We created superior material from nature's most abundant building block, cellulose.
Biotechnology

2018

At Lifebit, we're pushing forward the frontiers of health and knowledge by democratising access to omics data. We enable all researchers, whether novice or advanced, to run complex analyses and generate meaningful insights fast. Lifebit CloudOS is the world’s first federated genomics platform for unified and secure research over distributed big data - wherever data resides. From top tier pharmaceutical organisations to global research institutes to genetics companies and more, Lifebit CloudOS leads the way with our best-in-class UX/UI, seamless integration to open-source tools, marketplace of proprietary ones, powerful cohort browser, and advanced AI functionality. At Lifebit, we are open source pioneers, innovators redefining our industry. Our driving mission - to revolutionise bioinformatics and biomedical data analysis forever. We are growing fast and looking for more superstars to join our team.
Biotechnology

2017

YSOPIA Bioscience is a clinical-stage biotech company developing cutting-edge biotherapies based on the gut microbiome. Our goal is to bring safe & efficient solutions to patients with high unmet medical needs.
Biotechnology

2010

Created in 2003, Modul-Bio is an innovative company specialized in IT solutions for biological sample management providing barcoding systems, LIMS (Laboratory Information Management System) software and collaborative tools for sharing biological sample collections.
Biotechnology

2003

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems, 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type. Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease. Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications. Based in Cambridge, UK, the Company has raised over $40 million USD funding from Parkwalk, Ahren Innovation Capital, 24Haymarket, Trend Investment Group, Dr. Darrin M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management.
Biotechnology

2019

About Molecular Partners AG Molecular Partners AG is a clinical-stage biotech company that is developing a new class of therapies known as DARPin® therapeutics. The company attracts talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and virology. The company conducts research and development both internally and in partnerships with leading pharmaceutical companies and is backed by top biotech investors.
Biotechnology

2004

Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’ goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.
Biotechnology

2017

Based outside Edinburgh, Roslin Technologies Limited is an ambitious food and agriculture technology company which creates disruptive biotechnologies to improve how proteins are made. Our core capabilities lie in developing and commercialising a suite of unique animal stem cells and resources for the nascent global cultivated meat industry. We were the first company to commercialise pluripotent stem cells which continually self-renew and are able differentiate into the fat and muscle tissue required in the cultivated meat industry. In addition, we are now focussing our R&D on addressing key challenges in the sector including production cost reduction and process scale-up. We have developed unique animal cells that work; our cells can self-renew forever and differentiate into any tissue, including muscle and fat. Our cells are favourable for cultivated meat production since they address consumer concerns, make meat more affordable, and simplify regulatory approvals. Besides cells for cultivated meat, we continue to look for other biotechnologies that help us make protein production more sustainable.
Biotechnology

2016

rqmicro AG, based in Zurich, Switzerland, develops and markets proprietary reagents and innovative instruments for rapid microbiological tests for water and food safety. The new separation and detection technology is based on immunomagnetic separation and microfluidics and delivers accurate results at an unmatched speed. Common methods in microbiology need up to 14 days to give you semi-quantitative data. A waiting time that takes time and money. rqmicro reduces this delay significantly by providing precise quantitative results. With rqmicro. COUNT you can rapidly quantify specific pathogenic bacteria, such as Legionella and E. coli, or the total number of bacteria in water samples in up to 2 hours after taking samples. Discover more about rqmicro.COUNT. Visit our website: www.rqmicro.com
Biotechnology

2013

At Rhizocore, we develop technologies to grow symbiotic fungi that enhance the growth, resilience, and carbon sequestration potential of newly planted forests and woodlands. Whether it is for woodland restoration, commercial productivity, increasing tolerance to environmental stresses or capturing more carbon, our unique approach for growing locally-sourced mycorrhizal fungi ensures local adaptability to suit our customer's sites and needs. For more information email: info@rhizocore.com
Biotechnology

2021

For over twenty-five years we've been trading in used scientific equipment of almost every type and specification, giving us a broad base of knowledge which helps us assist our customers in sourcing the best value equipment on the market. Our ethos is rooted in our family approach—we are small, efficient and always ready to respond to the demands of our customers, some of whom we have been looking after for over twenty years. The team is headed by husband and wife Nick and Wendy Edmond and supported by their two sons Richard and Robert. Alongside them is a dedicated team dealing with sales, buying, administration and accounts. We deal with customers from universities, contract, private and public laboratories around the world. Our wealth of experience translates to excellent value for money for our customers, who are able to fully kit out laboratories or simply replace any old pieces of equipment at a fraction of the price of buying new. Don't hesitate to pick up the phone and let us know how we can help.
Biotechnology

1995

At SkylineDx, we live to make a difference. It is our mission to improve a patient’s quality of life by enabling them to benefit from personal insights at the genomic level of their disease. That means we are continuously innovating the world of gene signature-based diagnostic testing. Genes are responsible for making us who we are. It can determine our features such hair and eye color, skin tone, or even height. Although we know our genetic make-up is similar to one another, each individual is vastly unique. “No two humans are alike.” And while most agree on the quote above, the contrary is being practiced in disease treatment today. When a patient gets a cancer diagnosis, he or she is treated, more or less, the same as other patients with the same type of cancer. For decades we have known, but were not able to determine why patients with the same diagnosis respond differently to the same treatment. Today, after years of genetic research, we know that like humans, no two cancer cells are alike. And for that reason, we now know cancer treatments should differ case by case, because cancer cells are inherently different. At SkylineDx, we have a team of experts with the knowledge and capability to collaborate with highly respected physicians and patients advocates. Together we work to achieve the same multi-disciplinary goal: to give physicians the genetic tools to better guide the most affective treatment plan for their patients. This principle of individualized treatment plans is called personalized- or precision medicine and is extremely important for the patient. With the right personalized treatment, at the right moment, the patient can avoid side effects from over or undertreatment, which means less hospitalization, complications, medications, and ultimately better quality of life.
Biotechnology

2013

Synthace is a digital experiment platform built for high-performance life science R&D teams to help them run more powerful experiments and accelerate scientific progress. It allows biologists to design, plan, and automate experiments in a single place, then automatically gather structured experiment data and metadata in a unified no-code environment.
Biotechnology

2011

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. Innate has been a pioneer in the understanding of natural killer cell (NK cell) biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca. Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Biotechnology

1999

Intelliseq provides state of the art solutions for next generation sequencing. A team of passionate and skilled bioinformaticians, geneticists and molecular biologists approaches next generation DNA sequencing challenges with creativity and flexibility.
Biotechnology

2013

Pathology News is an exclusive community for pathologists and medical scientists interested in digital pathology, computational pathology, AI, tissue multiplexing, other trailblazing technologies and hot topics for pathology. Check out our scientific blog, industry news, careers, upcoming conferences and events, and use our exclusive Technology Buyer's Database to explore and search for scanners and other image capture devices, image management, image analysis and AI solutions, and contract service providers.
Biotechnology

2020

Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a French-Belgian biotech company that develops an innovative class of active immunotherapies to treat cancers. This cancer vaccine contains proprietary, potent, and scalable plasmacytoid dendritic cell line (PDC*line), whose remarkable characteristics make them excellently suited for immunotherapy. PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors. PDC*line offers unique advantages: - PDC*line is a professional and universal antigen-presenting cell much more potent than conventional (myeloid) Dendritic cells; - unlike conventional autologous Dendritic Cells, PDC*line is very easy to expand in large quantities in bioreactors (no need of maturation factors) and having been exposed in vitro to targeted tumor antigens and irradiated, it can be stored for years. - The off-the-shelf product is thawed and injected to treat any patients with a cancer type expressing the selected antigens and expressing HLA-A2. Of note, different HLA may be used or added to extend the target population. - The approach is very versatile and applicable to any cancer type. Based on a first-in-human phase Ib study in melanoma, PDC*line Pharma focuses on the development of a clinical candidate for lung cancer (PDC*lung) and neoantigens (PDC*Neo). The company regroups a team of 42 persons led by Eric Halioua (CEO) and raised close to 61M€ in equity and loans since its foundation. March 2019, PDC*line Pharma granted exclusive license in South Korea and exclusive option in other Asian countries to LG Chem Life Sciences Company, for the development and commercialization of PDC*lung cancer vaccine for lung cancer. The total deal value is 108M€ (123M$) plus significant tiered royalties on net sales in Asia.
Biotechnology

2014

Melt&Marble’s mission is to become an enabler for the alternative protein industry by providing it with the best and tastiest fats. We do this by using precision fermentation to produce animal fats without the animal. By engineering microbial metabolism, we can dictate the structure and properties of the fats that our microbes are producing, allowing us to mimic any fat structure, as well as create completely new and better fats. The result: tastier plant-based foods, for consumers and the planet!
Biotechnology

2014

Solution d'éclairage intelligente pour l’optimisation de la croissance des plantes et la consommation énergétique associée.
Biotechnology

2018

List of Biotechnology companies in Europe

Company Name

Location

Category

Employees

Website

Brussels, Belgium

Health and Medical
+3
Health and Medical, Information Technology, Design Services, Science and Engineering

20-30

https://ovizio.com/

Cambridge, United Kingdom (UK)

Science and Engineering
Science and Engineering

50-100

https://sanogenetics.com/

Lausanne, Switzerland

Science and Engineering
Science and Engineering

50-100

https://saphetor.com/

Amsterdam, The Netherlands

Science and Engineering
Science and Engineering

50-100

https://scenicbiotech.com/about/

Bristol, United Kingdom (UK)

Science and Engineering
Science and Engineering

10-20

https://sciencecreates.co.uk/

Tallinn, Estonia

Science and Engineering
Science and Engineering

10-20

https://selfdiagnostics.eu/

Montpellier, France

Science and Engineering
Science and Engineering

50-100

https://seqone.com/

Oxford, United Kingdom (UK)

Science and Engineering
Science and Engineering

30-50

https://www.theolytics.com/

Espoo, Finland

Science and Engineering
Science and Engineering

20-30

http://www.uniqbioresearch.com/

Madrid, Spain

Manufacturing and Industry
+2
Manufacturing and Industry, Health and Medical, Science and Engineering

30-50

http://www.algenex.es

Cambridge, United Kingdom (UK)

Science and Engineering
Science and Engineering

100-150

https://biomodal.com/

Glasgow, United Kingdom (UK)

Health and Medical
+1
Health and Medical, Science and Engineering

2-10

https://www.causewaytherapeutics.com/

Edinburgh, United Kingdom (UK)

Science and Engineering
Science and Engineering

2-10

https://emimaging.com/

Rotterdam, The Netherlands

Health and Medical
+1
Health and Medical, Science and Engineering

500-1000

https://www.argenx.com/

The Hague, The Netherlands

Health and Medical
+3
Health and Medical, Food and Beverages, Manufacturing and Industry, Science and Engineering

2-10

https://sibo.tech/

La Tour-de-peilz, Switzerland

Science and Engineering
Science and Engineering

2-10

https://limula.ch/

London, United Kingdom (UK)

Health and Medical
+1
Health and Medical, Science and Engineering

30-50

https://hertilityhealth.com/

Altrincham, United Kingdom (UK)

Science and Engineering
Science and Engineering

2-10

https://utilitytherapeutics.com/

Helsinki, Finland

Science and Engineering
Science and Engineering

10-20

https://www.valotx.com/

Madrid, Spain

Science and Engineering
Science and Engineering

2-10

https://thytech.com/

Helsinki, Finland

Science and Engineering
Science and Engineering

20-30

https://tiltbio.com/

Finland, Finland

Science and Engineering
Science and Engineering

20-30

https://herantis.com/

Barcelona, Spain

Science and Engineering
Science and Engineering

20-30

https://www.librefoods.co/

Reykjavík, Iceland

Health and Medical
+1
Health and Medical, Science and Engineering

500-1000

https://www.alvotech.com/

Zaragoza, Spain

Sales and Marketing
+3
Sales and Marketing, Health and Medical, Science and Engineering, Electronics

50-100

https://www.bitbrain.com/

Kongens Lyngby, Denmark

Science and Engineering
Science and Engineering

100-150

https://aquaporin.com/?utm_source=enterpriseleague.com

Paris, France

Science and Engineering
Science and Engineering

50-100

http://www.enterome.com

PARIS, France

Science and Engineering
Science and Engineering

2-10

http://www.coavetx.com

London, United Kingdom (UK)

Science and Engineering
Science and Engineering

20-30

http://www.basecamp-research.com

Manchester, United Kingdom (UK)

Science and Engineering
Science and Engineering

2-10

https://www.brightbiotech.co.uk

Milano, Italy

Science and Engineering
Science and Engineering

10-20

http://canax.com

Søborg, Denmark

Science and Engineering
Science and Engineering

2-10

http://cellugy.com

London, United Kingdom (UK)

Science and Engineering
Science and Engineering

100-150

https://lifebit.ai

Bordeaux, France

Science and Engineering
Science and Engineering

10-20

https://ysopia.bio/

Marseille, France

Science and Engineering
Science and Engineering

20-30

https://www.modul-bio.com

Cambridge, United Kingdom (UK)

Science and Engineering
Science and Engineering

50-100

http://www.mogrify.co.uk

Schlieren-Zürich, Switzerland

Science and Engineering
Science and Engineering

100-150

http://www.molecularpartners.com

Lausanne, Switzerland

Science and Engineering
Science and Engineering

20-30

http://www.oculis.com

Edinburgh, United Kingdom (UK)

Science and Engineering
Science and Engineering

20-30

https://www.roslintech.com

Zürich-Schlieren, Switzerland

Science and Engineering
Science and Engineering

10-20

https://www.rqmicro.com/

Edinburgh, United Kingdom (UK)

Science and Engineering
Science and Engineering

20-30

https://www.rhizocore.com/

Chorley, United Kingdom (UK)

Science and Engineering
Science and Engineering

10-20

http://www.richmondscientific.com

Rotterdam, The Netherlands

Science and Engineering
Science and Engineering

50-100

http://www.skylinedx.com

London, United Kingdom (UK)

Science and Engineering
Science and Engineering

50-100

http://www.synthace.com

Marseille, France

Science and Engineering
Science and Engineering

200-500

https://www.innate-pharma.com/

Kraków, Poland

Science and Engineering
Science and Engineering

10-20

https://intelliseq.com/

Stratford-upon-avon, United Kingdom (UK)

Science and Engineering
Science and Engineering

2-10

https://www.pathologynews.com

Liège, Belgium

Science and Engineering
Science and Engineering

20-30

http://www.pdc-line-pharma.com

Göteborg, Sweden

Science and Engineering
Science and Engineering

10-20

https://meltandmarble.com/

Lyon, France

Science and Engineering
Science and Engineering

20-30

http://www.horticulture.red

200/480 results

Frequently asked questions

Updated 23 October 2026

What is Enterprise League?

Enterprise League is a free business directory that helps buyers find the right company by sector and country. Every company has a profile showing what it does, what it offers and how to get in touch.

Is it free to list my company?

Yes, and it stays free: no card, no paid tier. Your profile appears in search results and category pages, can show up to 20 products and services, and lets buyers message you or ask for a quote.

How does verification work, and what does it cost?

Verifying your company is free. Confirm a code we email to an address at your company’s website, or send a company registration document for our team to check, and the verified badge appears on your profile. To show the badge in the directory and search results as well, take out a subscription: the first 14 days are free, and the price is on our pricing page.

Where does the company information come from?

Most profiles are built from public sources, such as official company registers. Claim your company’s profile to correct its details and add your own.

How do I claim or correct my company’s profile?

Open your company’s profile and choose Claim Profile. If you use an email address at your company’s website, a 6-digit code makes the profile yours at once; otherwise our team reviews your request, usually within a few days. Spotted a mistake on a company that isn’t yours? Tell us through our contact page.